amoxicillin / Generic mfg. - LARVOL DELTA

Optimal dosing of amoxicillin in obese and post-gastric bypass patients using a population pharmacokinetics-pharmacodynamics model approach. (PubMed, J Antimicrob Chemother) - "Amoxicillin doses of 1000 mg q6h were found to maximize the probability of attaining the PK/PD target with MIC ≤ 1 mg/L in obese and post-RYGB patients."

Journal • PK/PD data • Genetic Disorders • Obesity

Assessing behaviours in antimicrobial prescribing and implants in the UK: a pilot study. (PubMed, Prim Dent J) - "This study highlighted a lack of national antibiotics prescription guidelines and a lack of consistency in implant dentistry practice in the UK. It also indicated the need for multi-centre studies with large sample sizes that can support the foundation for appropriate guidelines on antibiotic prescribing in implant dentistry."

Journal • Infectious Disease • Orthopedics • Pain

Efficacy of nonsurgical periodontal treatment on patients with periodontitis and type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis. (PubMed, Acta Odontol Scand) - "SRP combined with local SZ may improve PD and CAL in patients with periodontitis and T2DM. Systemic AMX may enhance BOP outcomes, while DOXY or aPDT may help reduce HbA1c. DL may contribute to better FBS improvement."

Clinical • Journal • Retrospective data • Review • Dental Disorders • Diabetes • Inflammation • Metabolic Disorders • Periodontitis • Type 2 Diabetes Mellitus

Genomic epidemiology of a novel Pandoraea pneumonica group caused severe bloodstream infection in Hainan, China, 2021-2024. (PubMed, Front Cell Infect Microbiol) - "30 purified Pandoraea isolates showed high degree of MIC values to Meropenem, Amoxicillin and Potassium Clavulanate, Gentamicin, and Ceftazidime. Such cluster remains a critical public health challenge due to their regional epidemiological patterns and antibiotic treatment risk. This study contributed to the basis on pathogen identification, disease diagnosis, and BSI treatment."

Journal • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases

The Effects of High-dose Dual Therapy With Probiotics on Gut Microbiota for Helicobacter Pylori Rescue Treatment (clinicaltrials.gov) - P=N/A | N=72 | Completed | Sponsor: Zhongshan Hospital (Xiamen), Fudan University | Recruiting ➔ Completed

Trial completion • Infectious Disease • Metabolic Disorders

Eradication of Helicobacter pylori that contributes to hepatogenic ulcer is beneficial to the healing of hepatogenic ulcer. (PubMed, BMC Gastroenterol) - P=N/A | "Hp is a contributor to HU and an integrated strategy consisting of rabeprazole, amoxicillin and levofloxacin is effective in the treatment of HU, providing a potential application for HU patients."

Journal • Dyspepsia • Fibrosis • Gastroenterology • Hepatology • Immunology • Infectious Disease • Liver Cirrhosis • Peptic Ulcer

Unpacking Oral Challenge Protocols: A Descriptive Epidemiologic Study of Reactions, Predictors, and Practices for Delabeling Low-Risk Penicillin Allergies Leveraging Data from a Systematic Review and Meta-Analysis. (PubMed, Hosp Pharm) - "Background: Oral challenges with amoxicillin or other penicillins are safe and effective for delabeling low-risk penicillin allergy histories...However, although these delabeling strategies are becoming more prevalent, continued study of standardized protocols and follow-up are essential for effective and replicable delabeling strategies. Future research should prioritize diverse populations and equity-driven frameworks to improve generalizability to all individuals and to resource limited settings."

Journal • Retrospective data • Allergy • Immunology

A New Strategy for Chronic Endometritis Treatment Using Fermented Soy Product (ImmuBalance™). (PubMed, J Reprod Infertil) - "A total of 819 women with CE were treated with antibiotics-1 (doxycycline, n=809) or IMB (n=10, Group 1)...Subsequently, 194 patients were treated with antibiotics-1 (n=4) or -2 (amoxicillin, azithromycin, and metronidazole, n=190), whereas 15 were treated with IMB (n=15, Group 2)...CE was treated in 100% of cases in Group 2 and 3 (15/15 and 4/4, respectively). Based on the findings of this study, administration of IMB may be effective in treating CE, especially following antibiotic treatment."

Journal • Endometriosis • SDC1

Campylobacter lari bacteremia during treatment of pure red cell aplasia following major ABO-mismatched hematopoietic stem cell transplantation (PubMed, Rinsho Ketsueki) - "A 68-year-old man who underwent haploidentical hematopoietic stem cell transplantation (HSCT) from a major ABO-incompatible donor with post-transplant cyclophosphamide for myelodysplastic syndromes developed pure red cell anemia and post-transfusion iron overload. The isolate was resistant to levofloxacin, and intravenous cefepime was given followed by maintenance therapy with oral amoxicillin. We here report the first case of C. lari bacteremia developing after allogeneic HSCT."

Journal • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Infectious Disease • Myelodysplastic Syndrome • Oncology • Transplantation

MODELLING OF EXPECTED AMOXICILLIN CONCENTRATIONS AIDS INTERPRETATION OF CLINICAL NON-INFERIORITY OF LOWER COMPARED TO HIGHER DAILY ORAL AMOXICILLIN DOSES IN A RANDOMISED CONTROLLED TRIAL (ESPID 2025) - "Conclusions/Learning Points Clinical non-inferiority of lower oral amoxicillin doses aligns with 80% children achieving ≥95% fT>MIC for the clinically relevant scenario (90 th percentile MICs imputed for missing values = 0.064mg/L). In settings with higher prevalence of pencillin-non-susceptible pneumococci, higher daily doses may be required."

Clinical • Head-to-Head • Human Immunodeficiency Virus • Infectious Disease • Pneumococcal Infections

DO THE REDEFINED EUCAST DEFINITIONS WARRANT ADJUSTMENT OF PAEDIATRIC ANTIBIOTIC DOSAGES? A PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELLING APPROACH (ESPID 2025) - "Method For amoxicillin, ceftazidime, cefuroxime, and ciprofloxacin, we used existing PBPK models and verified them with adult and paediatric clinical pharmacokinetic data. Conclusions/Learning Points In contrast to adults, there is no need to increase currently recommended paediatric antibiotic dosages for the included drugs. At the same time, further simulations showed that, in case of therapy failure, individualization of doses should be considered in both adults and children, especially in severe infections with micro-organisms with known relatively high minimal inhibitory concentrations."

PK/PD data • Infectious Disease

PRENATAL EXPOSURE TO AMBIENT FINE PARTICULATE MATTER POLLUTION AND AMOXICILLIN DISPENSATION IN INFANTS: NATIONAL BIRTH COHORT STUDY IN SCOTLAND (ESPID 2025) - "Conclusions/Learning Points Prenatal exposure to PM 2.5 was associated with an increased likelihood and frequency of amoxicillin dispensation during infancy, reflecting its potential impact on early life respiratory health. Targeted interventions to improve air quality during pregnancy may reduce the burden of antibiotic use."

Infectious Disease

IS THE MOLECULAR GENOTYPING OF ANTIBIOTIC RESISTANCE FOR HELICOBACTER PYLORI A TRUSTABLE TREATMENT GUIDE? (ESPID 2025) - "77,20% (n=105) patients completed treatment according to CLA mutation information, 22,85% (n=24) with amoxicillin and clarithromycin, and 66,67% (n=70) with amoxicillin and metronidazole. The efficacy is comparable to other series based on culture methods, highlighting the high sensitivity and effectiveness of PCR on therapy guides. Molecular diagnostics should be part of routine care to improve treatment precision and the future gold standard to tailor H. pylori eradication."

Infectious Disease • Novel Coronavirus Disease

Randomized multicenter trial comparing minocycline and ornidazole with classical quadruple therapy in Helicobacter pylori treatment. (PubMed, Sci Rep) - "This study evaluated the efficacy, safety, and cost of minocycline, ornidazole, esomeprazole, and bismuth (MOEB) therapy versus classical therapy (amoxicillin, clarithromycin, esomeprazole, and bismuth potassium citrate, ACEB) for Helicobacter pylori eradication. MOEB was also more cost-effective, with a direct cost of 675.7 CNY versus 970.1 CNY for ACEB, yielding an incremental cost-effectiveness ratio of -27.5 CNY per eradication rate. MOEB is a safe, effective, and cost-efficient first-line regimen for H. pylori eradication."

Clinical • Journal • Infectious Disease

Mucorales and Actinomyces Co-infection Presenting as Erosive Pulmonary Mass in a Neutropenic Patientmucorales and Actinomyces Co-infection Presenting as Erosive Pulmonary Mass in a Neutropenic Patient (ATS 2025) - "He underwent recent 1 cycle chemotherapy with venetoclax and decitabine...Of note patient was on outpatient posaconazole for fungal prophylaxis, however therapeutic levels of the drug were not achieved...However given underlying malignancy and tenuous clinical condition alongside profound thrombocytopenia, he elected a palliative approach to his overall diagnoses, and was discharged with isavuconazole and amoxicillin...The treatment of invasive Mucor infection requires both surgical debridement and anti-fungal therapy. In certain hosts such as this patient, surgical intervention is often noted to be of prohibitively high risk, which ultimately mitigates the clinician's ability to cure the infection."

Clinical • Hematological Disorders • Infectious Disease • Musculoskeletal Diseases • Oncology • Orthopedics • Pulmonary Disease • Respiratory Diseases • Septic Shock • Thrombocytopenia

DACAT: Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing (clinicaltrials.gov) - P2 | N=300 | Recruiting | Sponsor: Massachusetts General Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Allergy • Immunology

Genomic insights into virulence, biofilm formation and antimicrobial resistance of multidrug-resistant Helicobacter pylori strains of novel sequence types isolated from Vietnamese patients with gastric diseases. (PubMed, J Glob Antimicrob Resist) - "Phenotypic-antibiotic susceptibility testing was performed against amoxicillin, clarythromycin, metronidazol, tetracycline and levofloxacin using an E-test...Double amoxicillin-resistant mutations on pbp1 and pbp2, or a mutation on pbp3, triple clarithromycin-resistant mutations on 23S rRNA gene and a levofloxacin-resistant mutation on gyrA were detected in antibiotic-resistant strains...Finally, a rifamycin-resistant mutation in rpoB was also detected. This study provides insights into the genome of multidrug-resistant H. pylori strains of novel sequence type circulating in Vietnam for future investigations of its pathobiology and spread through human populations."

Journal • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Peptic Ulcer

The Effect of Vitamin D Supplement as Adjuvant Therapy in Eradication of Helicobacter Pylori Infection (clinicaltrials.gov) - P3 | N=70 | Not yet recruiting | Sponsor: Assiut University

New P3 trial • Infectious Disease

10-DAY VERSUS 14-DAY VONOPRAZAN AND AMOXICILLIN DUAL THERAPY FOR THE FIRST-LINE ERADICATION OF HELICOBACTER PYLORI INFECTION: A NATIONWIDE MULTICENTER, RANDOMIZED, CONTROLLED TRIAL (DDW 2025) - P4 | No abstract available

Clinical • Infectious Disease

POUCH FUNCTION AND CLINICAL OUTCOMES IN PREGNANCY AFTER ILEAL POUCH ANAL ANASTOMOSIS FOR ULCERATIVE COLITIS (DDW 2025) - "Antibiotics prescribed for acute pouchitis in pregnancy were: 45.5% amoxicillin, 45.5% metronidazole, and 9.1% vancomycin and post-partum were: 33.3% ciprofloxacin and 66.7% metronidazole...Treatments for CD of the pouch were: 61.9% anti-TNF, 14.3% ustekinumab, 9.5% vedolizumab, and 14.2% other medications... Women with UC and IPAA should be closely monitored during pregnancy and the post-partum period. Women with a prior history of inflammatory conditions of the pouch are at higher risk of pouch complications in pregnancy."

Clinical • Clinical data • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Hepatology • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

THE INFLUENCE OF SUPPLEMENTARY PROBIOTICS ON THE ADVERSE EVENTS AND FECAL DYSBIOSIS OF HELICOBACTER PYLORI ERADICATION - A DOUBLE BLIND, MULTI-CENTER RANDOMIZED, PLACEBO-CONTROLLED TRIAL (DDW 2025) - "Participants underwent 14-day sequential therapy: esomeprazole 40 mg and amoxicillin 1 g twice daily (days 1–7), then esomeprazole 40 mg, clarithromycin 500 mg, and metronidazole 500 mg twice daily (days 8–14), combined with a 2-month course of probiotics or placebo. Gut microbiota dysbiosis partially resolves similarly within a year in both groups. Further research is needed to understand probiotics' potential in promoting microbiota recovery after H. pylori eradication."

Adverse events • Clinical • Dysbiosis • Gastric Cancer • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Oncology • Peptic Ulcer • Solid Tumor

STUDY OF ANTIMICROBIAL RESISTANCE IN HELICOBACTER PYLORI BASED ON MOLECULAR TESTS BY NEXT GENERATION SEQUENCING IN LATIN AMERICAN COUNTRIES (DDW 2025) - "NGS was performed with the validated PyloriARI kit (American Molecular Laboratories, Chicago) for the genes: 23S rRNA, gyrA, 16S rRNA, pbp1, rpoB, and rdxA, to assess resistance to clarithromycin, fluoroquinolones, metronidazole, amoxicillin, tetracycline, and rifabutin, respectively. (figure 1) Conclusion : A high frequency of antimicrobial resistance in H. pylori infection was found, most importantly to clarithromycin and fluoroquinolones. These results underscore the need in LATAM to assess H. pylori resistance ecology at the regional level, implement antimicrobial stewardship programs, and develop novel H. pylori treatments."

Biomarker • Next-generation sequencing • Gastrointestinal Disorder • Infectious Disease

FOURTEEN-DAY VONOPRAZAN-BASED DUAL THERAPY WITH AMOXICILLIN AS FIRST-LINE HELICOBACTER PYLORI TREATMENT IN COMPARISON WITH EXTENDED SEQUENTIAL THERAPY: A RANDOMIZED CONTROLLED TRIAL IN TAIWAN (DDW 2025) - P4 | "Participants were randomly assigned to the VA-14 group (vonoprazan 20 mg + amoxicillin 1000 mg twice daily for 14 days) or the S-14 group (lansoprazole 30 mg + amoxicillin 1000 mg twice daily for 7 days, followed by lansoprazole 30 mg + clarithromycin 500 mg + metronidazole 500 mg twice daily for 7 days). Overall, compliance with taking all pills correctly was significantly higher in the VA-14 group (93.8%) compared to the S-14 group (90.0%) (Chi-square test, p = 0.04) Conclusions Our findings support the use of vonoprazan-based dual therapy with amoxicillin as a potential standard first-line treatment for H. pylori infection. Clinical Trial Registration: ClinicalTrials.gov, identifier NCT06156085 Keywords: Helicobacter pylori , Anti-Bacterial Agents, Proton Pump Inhibitors, Potassium-competitive acid blocker"

Clinical • Constipation • Gastric Cancer • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Oncology • Peptic Ulcer • Solid Tumor

OPTIMIZING H. PYLORI ERADICATION IN OBESE PATIENTS: THE IMPACT OF WEIGHT-ADJUSTED QUADRUPLE THERAPY (DDW 2025) - "All patients received a 14 day Quadruple Concomitant therapy consisting of pantoprazole, amoxicillin, clarithromycin and metronidazole. Weight-adjusted quadruple therapy demonstrated superior eradication rates compared to standard fixed-dose regimens in obese patients, emphasizing the importance of individualized antibiotic dosing in this population. Tailored treatment strategies should be prioritized to enhance eradication success and optimize patient outcomes"

Clinical • Diabetes • Genetic Disorders • Infectious Disease • Obesity

EFFICACY AND SAFETY OF HIGH-DOSE DUAL THERAPY WITH POTASSIUM-COMPETITIVE ACID BLOCKERS AND AMOXICILLIN FOR HELICOBATER PYLORI READICATION: A REAL-WORLD, RETROSPECTIVE, MULTICENTER CLINICAL STUDY (DDW 2025) - "The bismuth quadruple therapy group (BQT, n=512) received esomeprazole (20 mg, twice daily), potassium bismuth citrate (240 mg, twice daily), amoxicillin (1 g, twice daily), and clarithromycin (500 mg, twice daily). High-dose PA dual therapy demonstrates superior efficacy and a lower incidence of AEs in the treatment of H. pylori infection, making it particularly suitable for previously treated patients and middle-aged or older individuals."

Real-world • Real-world evidence • Retrospective data • Infectious Disease